| 2026年中报 | 2025年年报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| PVP-I(元) | 49,565,197.75 | 87,578,210.93 | 44,122,613.23 | 103,428,797.00 | 52,381,042.30 |
| PVPK30(元) | 205,868,487.84 | 341,093,859.15 | 182,553,265.43 | 492,147,848.16 | 260,846,436.82 |
| 分子诊断服务(元) | 3,761,928.39 | 11,211,338.48 | 5,581,966.86 | 31,060,830.99 | 14,023,989.44 |
| 基因检测技术服务(元) | 18,461,912.83 | 35,422,211.12 | 19,565,777.98 | 41,923,937.79 | 21,498,730.52 |
| 欧瑞姿系列(元) | 73,531,464.39 | 112,841,984.79 | 95,314,196.88 | 182,928,385.16 | 84,748,464.41 |
| 医疗服务(元) | 31,948,918.16 | 53,368,730.34 | 22,229,514.02 | 40,655,703.08 | 18,480,680.44 |
| 肿瘤早期诊断(元) | 17,273,397.45 | 38,446,927.80 | 19,831,410.01 | 41,105,869.25 | 20,985,937.52 |
| PVP系列其他产品(元) | 277,702,774.65 | 498,128,702.73 | 254,815,588.38 | 673,068,656.88 | 261,839,181.51 |
| 营业成本(元) | |||||
| PVP-I(元) | 38,811,814.47 | 67,517,418.06 | 35,547,630.69 | 70,452,085.73 | 34,076,436.03 |
| PVPK30(元) | 157,888,427.48 | 232,518,261.98 | 146,808,053.04 | 304,936,595.41 | 128,076,859.75 |
| 分子诊断服务(元) | 2,501,188.47 | 5,694,773.61 | 2,930,986.10 | 16,444,058.39 | 7,282,743.78 |
| 基因检测技术服务(元) | 16,768,459.94 | 34,784,039.14 | 18,803,581.10 | 36,604,144.78 | 18,624,676.60 |
| 欧瑞姿系列(元) | 28,121,260.73 | 38,424,893.26 | 28,047,646.79 | 67,010,644.70 | 30,905,350.09 |
| 医疗服务(元) | 19,587,198.02 | 33,174,076.70 | 12,848,599.16 | 25,051,709.88 | 8,962,717.53 |
| 肿瘤早期诊断(元) | 6,157,527.70 | 14,913,169.45 | 7,538,320.54 | 16,391,443.63 | 7,593,986.24 |
| PVP系列其他产品(元) | 141,694,458.91 | 211,945,599.33 | 114,709,653.87 | 315,277,569.94 | 94,089,530.08 |
| 毛利(元) | |||||
| PVP-I(元) | 10,753,383.28 | 20,060,792.87 | 8,574,982.54 | 32,976,711.27 | 18,304,606.27 |
| PVPK30(元) | 47,980,060.36 | 108,575,597.17 | 35,745,212.39 | 187,211,252.75 | 132,769,577.07 |
| 分子诊断服务(元) | 1,260,739.92 | 5,516,564.87 | 2,650,980.76 | 14,616,772.60 | 6,741,245.66 |
| 基因检测技术服务(元) | 1,693,452.89 | 638,171.98 | 762,196.88 | 5,319,793.01 | 2,874,053.92 |
| 欧瑞姿系列(元) | 45,410,203.66 | 74,417,091.53 | 67,266,550.09 | 115,917,740.46 | 53,843,114.32 |
| 医疗服务(元) | 12,361,720.14 | 20,194,653.64 | 9,380,914.86 | 15,603,993.20 | 9,517,962.91 |
| 肿瘤早期诊断(元) | 11,115,869.75 | 23,533,758.35 | 12,293,089.47 | 24,714,425.62 | 13,391,951.28 |
| PVP系列其他产品(元) | 136,008,315.74 | 286,183,103.40 | 140,105,934.51 | 357,791,086.94 | 167,749,651.43 |
| 毛利率(%) | |||||
| PVP-I(%) | 21.70 | 22.91 | 19.43 | 31.88 | 34.95 |
| PVPK30(%) | 23.31 | 31.83 | 19.58 | 38.04 | 50.90 |
| 分子诊断服务(%) | 33.51 | 49.21 | 47.49 | 47.06 | 48.07 |
| 基因检测技术服务(%) | 9.17 | 1.80 | 3.90 | 12.69 | 13.37 |
| 欧瑞姿系列(%) | 61.76 | 65.95 | 70.57 | 63.37 | 63.53 |
| 医疗服务(%) | 38.69 | 37.84 | 42.20 | 38.38 | 51.50 |
| 肿瘤早期诊断(%) | 64.35 | 61.21 | 61.99 | 60.12 | 63.81 |
| PVP系列其他产品(%) | 48.98 | 57.45 | 54.98 | 53.16 | 64.07 |
| 收入构成(%) | |||||
| PVP-I(%) | 7.31 | 7.43 | 6.85 | 6.44 | 7.13 |
| PVPK30(%) | 30.36 | 28.95 | 28.35 | 30.64 | 35.50 |
| 分子诊断服务(%) | 0.55 | 0.95 | 0.87 | 1.93 | 1.91 |
| 基因检测技术服务(%) | 2.72 | 3.01 | 3.04 | 2.61 | 2.93 |
| 欧瑞姿系列(%) | 10.84 | 9.58 | 14.80 | 11.39 | 11.53 |
| 医疗服务(%) | 4.71 | 4.53 | 3.45 | 2.53 | 2.52 |
| 肿瘤早期诊断(%) | 2.55 | 3.26 | 3.08 | 2.56 | 2.86 |
| PVP系列其他产品(%) | 40.95 | 42.28 | 39.57 | 41.90 | 35.63 |
| 毛利构成(%) | |||||
| PVP-I(%) | 4.03 | 3.72 | 3.10 | 4.37 | 4.52 |
| PVPK30(%) | 18.00 | 20.14 | 12.91 | 24.82 | 32.77 |
| 分子诊断服务(%) | 0.47 | 1.02 | 0.96 | 1.94 | 1.66 |
| 基因检测技术服务(%) | 0.64 | 0.12 | 0.28 | 0.71 | 0.71 |
| 欧瑞姿系列(%) | 17.03 | 13.80 | 24.30 | 15.37 | 13.29 |
| 医疗服务(%) | 4.64 | 3.75 | 3.39 | 2.07 | 2.35 |
| 肿瘤早期诊断(%) | 4.17 | 4.37 | 4.44 | 3.28 | 3.31 |
| PVP系列其他产品(%) | 51.02 | 53.08 | 50.62 | 47.44 | 41.40 |